ITEK Inotek Pharmaceuticals Corporation

1.36
+0.05  (4%)
Previous Close 1.31
Open 1.30
Price To book 0.64
Market Cap 36733875
Shares 27,010,202
Volume 890,676
Short Ratio 4.45
Av. Daily Volume 1,069,846

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data released January 3, 2017. Primary endpoint not met.
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 2 trial failed - noted July 7, 2017.
Trabodenoson and latanoprost
Glaucoma

Latest News

  1. Today's Research Reports on Stocks to Watch: Inotek Pharmaceuticals and 22nd Century Group
  2. INSERTING and REPLACING Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases
  3. Inotek Pharmaceuticals reports 2Q loss
  4. Inotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights
  5. Lexington’s Inotek suggests it could explore sale after another trial flop
  6. Featured Company News – Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate Update
  7. Today's Research Reports on Stocks to Watch: Ocular Therapeutix and Inotek Pharmaceuticals
  8. Inotek to consider strategic options after eye drug fails another study
  9. Inotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dose Combination Trial of Trabodenoson and Provides Corporate Update
  10. Options Traders Expect Huge Moves in Inotek Pharmaceuticals (ITEK) Stock
  11. Inotek Pharmaceuticals Corporation Reports First Quarter 2017 Financial Results and Operational Highlights
  12. Inotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting
  13. Blog Coverage Inotek Announces Completion of Recruitment in Phase-2 Study for Glaucoma
  14. Inotek Completes Patient Recruitment in Phase 2 Trial of a Fixed-dose Combination (FDC) of Trabodenoson and Latanoprost
  15. Inotek Pharmaceuticals Financial Review Potential Value Drivers and Drug Pipeline
  16. Inotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results and Operational Highlights
  17. Today's Research Reports on Biotech Stocks to Watch: Inotek Pharmaceuticals and Tetraphase Pharmaceuticals
  18. 24 HOUR DEADLINE NOTICE FOR ITEK INVESTORS: Lundin Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm